



an Open Access Journal by MDPI

## Pancreatic Cancer: From Novel Biomarkers to More Efficient Therapies

Guest Editor:

### Dr. Ingrid Garajová

Medical Oncology Unit, University Hospital of Parma, 43125 Parma, Italy

Deadline for manuscript submissions:  
**closed (31 October 2023)**

### Message from the Guest Editor

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult tumors to treat. Radical surgery is the only potentially curative treatment, though, even in the group of radically resected patients, the five-year survival rate is below 25%. There are several reasons for the dismal prognosis of PDAC, in particular the late onset of symptoms, the biological aggressiveness characterized by early metastasis and the impressive resistance to many anticancer agents.

Unfortunately, progress in the management of both resectable and borderline resectable PDAC, but especially of locally advanced/metastatic disease, has been very modest in recent decades. Novel therapies and biomarkers are needed in order to predict effectiveness/resistance to treatments.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- predictive and prognostic biomarkers in PDAC
- translational research with the potential to increase the efficacy of actual treatments
- neoadjuvant therapy in resectable/borderline resectable PDAC
- adjuvant therapy in PDAC
- metastatic treatment possibilities in PDAC



[mdpi.com/si/150864](https://mdpi.com/si/150864)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

**Journal Rank:** JCR - Q2 (Oncology)

## Contact Us

---

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currnocol](http://mdpi.com/journal/currnocol)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)